


MULTIDISCIPLINARY
THORACIC CANCERS
SYMPOSIUM



BRINGING PERSONALIZED CARE TO YOUR PATIENTS

HILTON SAN DIEGO BAYFRONT
SAN DIEGO | MARCH 14-16, 2019

**News Briefing: Highlights from the 2019
Multidisciplinary Thoracic Cancers Symposium**

Improved Overall Survival with Local Consolidative Therapy in Oligometastatic Non-Small Cell Lung Cancer: Results from a Cohort of 194 Patients with Synchronous Disease

Kyle G. Mitchell¹, Ahsan Farooqi², Ethan B. Ludmir², Erin M. Corsini¹, Ara A. Vaporciyan¹,
Stephen G. Swisher¹, John V. Heymach³, Jianjun Zhang³, Daniel R. Gomez², and Mara B.
Antonoff¹

¹*Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center*

²*Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center*

³*Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center*



Disclosure for Dr. Corsini

- Employer: The University of Texas MD Anderson Cancer Center
- I have nothing to disclose.




Oligometastatic NSCLC

Advanced NSCLC

- Frequently present at diagnosis
- Associated with dismal prognosis

Oligometastatic state: limited disease burden¹

- Distinct tumor biology^{2,3}
- Spectrum of associated outcomes



¹Hellman *J Clin Oncol* 1995; ²Wong *Cancer* 2016; ³Lussier *PLoS One* 2011; Figure: Gomez 2016


Oligometastatic NSCLC

Advanced NSCLC

- Frequently present at diagnosis
- Associated with dismal prognosis

Oligometastatic state: limited disease burden¹

- Distinct tumor biology^{2,3}
- Spectrum of associated outcomes



¹Hellman *J Clin Oncol* 1995; ²Wong *Cancer* 2016; ³Lussier *PLoS One* 2011; Figure: Gomez 2016

Objectives and Hypothesis

Objectives: In synchronous oligometastatic (≤ 3 sites) NSCLC

- Characterize survival outcomes associated with LCT
- Define subgroups deriving greatest therapeutic benefit

Hypothesis: Local consolidative therapy \rightarrow improved overall survival

Clinicopathologic Characteristics (N=194)

Variable	N (%) or Median (IQR)
Age (years)	62 (57-69)
Sex (M)	111 (57%)
Histology	
Adenocarcinoma	149 (77%)
Squamous	34 (18%)
NSCLC NOS	11 (6%)
Thoracic Stage	
I	37 (19%)
II	42 (22%)
III	115 (59%)

Variable	N (%) or Median (IQR)
# of Metastatic Sites	
1	57 (29%)
2	103 (53%)
3	34 (18%)
Location of Metastases	
Brain	86 (44%)
Bone	51 (26%)
Adrenal	36 (19%)
Liver	7 (4%)

Clinicopathologic Characteristics (N=194)

Variable	N (%) or Median (IQR)
Age (years)	62 (57-69)
Sex (M)	111 (57%)
Histology	
Adenocarcinoma	149 (77%)
Squamous	34 (18%)
NSCLC NOS	11 (6%)
Thoracic Stage	
I	37 (19%)
II	42 (22%)
III	115 (59%)

Variable	N (%) or Median (IQR)
# of Metastatic Sites	
1	57 (29%)
2	103 (53%)
3	34 (18%)
Location of Metastases	
Brain	86 (44%)
Bone	51 (26%)
Adrenal	36 (19%)
Liver	7 (4%)

Comprehensive LCT to all sites (cLCT):

121 (62%)

Subcomprehensive or No LCT to metastases (no LCT):


73 (38%)

Survival Outcomes (N=194)

Group	N	MST	95% CI
Comprehensive LCT	121	29 months	25-42 months
No cLCT	73	23 months	16-35 months

Group	N	1yOS	3yOS	5yOS
Comprehensive LCT	121	85%	43%	32%
No cLCT	73	72%	35%	19%


Median follow-up duration 52 months (IQR 48-66)




Survival Outcomes Among Patients Undergoing cLCT (N=121)

Associated with poorer survival:



- Squamous histology
- Higher intrathoracic stage
- Bone metastases



Patterns of Treatment Failure (cLCT, N=121)



Patterns of Treatment Failure (cLCT, N=121)



Conclusions

- Local consolidative therapy to all sites of disease associated with improved overall survival
 - 3-year OS: 43%
 - 5-year OS: 32%
- Best outcomes: Adenocarcinoma, thoracic stage I/II, no bone metastases
- Further work needed to characterize in context of contemporary systemic therapies



Interview Requests & Other Questions

press@astro.org

703-286-1600

Slides and a recording of this briefing will be available online:

www.astro.org/thoracicpress

